Sphingosine-1-phosphate receptor 2 (S1PR2) plays an essential role in regulating blood-brain barrier (BBB) function during demyelinating central nervous system (CNS) disease. Increased expression of S1PR2 occurs in disease-susceptible CNS regions of female versus male SJL mice and in female multiple sclerosis (MS) patients. Here we reported a novel sensitive and noninvasive method to quantitatively assess S1PR2 expression using a C-1l labeled positron emission tomography (PET) radioligand [ 11 C]5a for in vivo imaging of S1PR2.
Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
Accepted Manuscript
Organic & Biomolecular Chemistry www.rsc.org/obc
Introduction
Multiple sclerosis (MS) is a neuroinflammatory demyelinating disease of the central nervous system (CNS) which leads to focal plaques of primary demyelination in conjunction with BBB disruption in the gray and white matter of the brain and spinal cord.
1, 2 MS affects 2.5 million people worldwide with a prevalence of approximately 0.1% in the Caucasian population. 3 The life expectancy of patients with MS is significantly reduced and the quality of life is adversely affected in terms of mobility and social functioning. MS also has a strong sex bias, with the female to male ratio currently approaching 4:1. [4] [5] [6] Relapsing-remitting MS (RRMS), the most common form of the disease in women, is a condition in which recurrent episodes of new neurological dysfunction (relapses) are separated by periods of clinical stability (remission). Most RRMS patients (>50%)
will develop secondary progressive MS (SPMS), with increased and sustained disability within 10 -20 years after diagnosis. 7, 8 The mechanisms of that contribute to progression of MS are incompletely understood.
Sphingolipids, main components of nervous tissue, have been linked to MS several decades ago. Nowadays, especially sphingosine-1-phosphate (S1P) is in the focus of pathophysiological research and therapy development. S1P is a membrane-derived lysophospholipid that binds with five subtype G-protein coupled receptors S1PR1-S1PR5. The activation of S1PRs modulates a spectrum of key biological events including activities in the CNS and immune response. 9 Sphingolipid-like immunomodulator fingolimod (FTY-720, Gilenya) is the first oral disease-modifying therapy approved by the US Food and Drug Administration (FDA) for RRMS. 10 Phosphorylated Fingolimod sequesters lymphocytes within the lymph nodes and prevents their trafficking to the CNS, via binding to S1PR subtypes S1PR1, S1PR3, S1PR4, and S1PR5, but not S1PR2.
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Encouraged by the success of Fingolimod, much effort has been devoted to developing selective compounds targeting S1PR subtypes, especially S1PR1 or S1PR2. 12 In a recent study, we found increased expression of S1PR2 in disease-susceptible CNS regions of female MS patients, and suggest cell intrinsic sex differences in the S1PR2 expression on CNS vasculature contribute to the development of disease cycles in females compared with males. 13 Quantification of S1PR2 levels would greatly contribute to studies examining sex differences in MS, and the identification of patients that may benefit from treatment using S1PR2 antagonists, which are less likely to cause lymphopenia. 14 Combined with a suitable radiotracer, positron emission tomography (PET), a reliable well established noninvasive imaging method, is able to offer a unique sensitive way to quantitatively assess neurotransmitter receptors, enzymes, and transporters in vivo. 15 Currently PET is widely used in clinical diagnosis. Identifying a suitable PET tracer that can specifically assess the expression of S1PR2 in vivo, will ultimately lead to better understanding of the function of S1PR2 in the neuropathogenesis of MS.
The inbred SJL mouse strain has been used as a model of the sexual dimorphism observed in MS, as SJL females are more susceptible to experimental autoimmune encephalomyelitis (EAE) than males; and exhibit a relapsing-remitting disease pattern similar to that observed in MS patients. 16, 17 Moreover, sex difference has also been found in the CNS expression of S1PR2 in SJL mice, especially in the cerebellum, 13 which provides a good target for the validation of new-synthesized S1PR2 radioligands.
Herein we report the design and synthesis of a series of S1PR2 ligands containing similar core structures as the well-known S1PR2 selective antagonist JTE-013. 18 In vitro competitive cell membrane binding assays are conducted to determine the binding affinities of the newly synthesized analogues towards S1PR1, S1PR2, and S1PR3. Radiosynthesis of a S1PR2 radioligand [ demonstrates sexual dimorphism of S1PR2 expression in the cerebellum of SJL mice.
Results

Chemistry
The synthesis of S1PR2 ligands starts with the construction of key hydrazine intermediate 3. Condensation of 5-amino-1,3-dimethylpyrazole with ethyl isobutyrylacetate using acetic acid as the solvent afforded compound 1. 19 The reaction yield was low when propionic acid was employed as the solvent. Moreover, it's very challenging to remove the acylating side product from the reaction of 5-amino-1,3-dimethylpyrazole with solvent propionic acid due to its close polarity as the product. However, use of acetic acid as the solvent allowed the separation of the product from the acylated side product. Bromination of 1 afforded compound 2, followed by reaction with hydrazine to produce the key intermediate 3. The 2-chloropyridine moiety was synthesized from commercially available 2-chloro-6-methoxyisonicotinic acid. Treatment of 2-chloro-6-methoxyisonicotinic acid with diphenylphosphoryl azide afforded acyl azide 4. Reflux of compound 4 in toluene in situ produced the isocyanate. A solution of hydrazine 3 in tetrahydrofuran (THF) was subsequently added to the above solution to give the first target compound 5a in moderate yield (Scheme 1). Next we focused on the modification of the methoxy group in compound 5a to explore new analogues targeting on S1PR2. The syntheses of the target compounds 5b -5f are depicted in Scheme 2. Reaction of methyl 2-chloroisonicotinate with silver (II) fluoride, followed a reported procedure 20 to introduce a fluorine atom on the pyridine ring to generate compound 6. Saponification of compound 6 gave carboxylic acid 7 in quantitative yield. Conversion of the acid to azide provided acyl azide 8, which was further reacted with hydrazine 3 to give target compound 5b. By replacing one of the chlorine atoms in 2,6-dichloroisonicotinic acid with methoxyethoxy functional group generated intermediate 9, which was readily converted to target compound 5c using a similar procedure for preparing compound 5a. Alternatively, hydrolysis of 2,6-dichloroisonicotinic acid with aqueous sodium hydroxide solution at 130 °C , followed by precipitation of the product by acidification using 6 M HCl, produced the compound 11 in high yield. Protection of 11 with chloromethyl methyl ether afforded two regioisomers 12 and 13 in a 5/1 ratio, which were readily separated.
The esters were saponified to afford acids 14 and 16 in high yields. Both compounds were converted to the acyl azide and reacted with hydrazine 3 to provide target compounds 5d and 5e. Attempts to remove the MOM protecting group in compound 5e using hydrogen chloride/dioxane led to a complex resulted from the poor solubility of compound 5e in the solvent. To resolve the difficulty, deprotection of the MOM group of 5e was accomplished by using trifluoroacetic acid in dichloromethane that smoothly produced the C-11 radiolabeling 
In vitro competitive binding assay
The in vitro competitive binding assays against [ 32 P]-S1P for the new synthesized target compounds 5a -5f
were conducted following our published protocol. 21 Results showed that compounds 5a, 5e, and 5f exhibited promising binding potency with IC 50 value of 9.52 ± 0. importantly, compound 5a was seven-fold more potent than the well-known S1PR2 antagonist -JTE-013 (IC 50 = 68.47 ± 7.45 nM, Figure 1 ) and also showed good selectivity towards S1P1 and S1P3 receptors (IC 50 > 1000 nM) ( Table 1) . Compounds 5a, 5e, 5f showed similar calculated LogD 7.4 values as JTE-013 except the calculated LogD 7.4 for compound 5d was 1.01, which may cause its lose binding potency for S1PR2. 
Radiochemistry
With the promising in vitro competitive binding potency for several ligands having IC 50 < 10 nM, we elected to radiolabel 5a using [ (decayed to the end of bombardment (EOB), n > 10), specific activity of 6 -10 Ci/µmol (EOB). 
Biodistribution study
Biodistribution studies were conducted to assess the tracer uptake in the brain and peripheral organs/tissues.
The uptake of [ 11 C]5a in female SJL mice at 30 min post injection showed that the heart, lung, kidney and liver had the highest uptake, which was consistent with S1PR2 distribution in mice. 22 The cerebellum and total brain Table 2 . 
Ex vivo autoradiography and microPET/ computerized tomography (CT) study
To further validate the application of [ 11 C]5a for imaging S1PR2, ex vivo autoradiography studies and microPET/CT scans in male and female SJL mice with CsA pre-treatment were also performed. The results from both autoradiography and PET/CT studies consistently demonstrated higher accumulation of [ 11 C] 5a in the cerebellum of female SJL mice than that observed in males (indicated by white dashed circles in Figure   2A ). Furthermore, quantitative microPET analysis showed that the average cerebellar uptake of [ 11 C]5a in female mice was statistically higher (n = 5, p = 0.021) than that in male mice (standardized uptake values (SUV) 0.58 ± 0.16 vs 0.48 ± 0.12, Figure 2B ). The autoradiography and microPET/CT scans clearly demonstrated a sex difference in the cerebellar tracer uptake of [ 11 C]5a in SJL mice and was consistent with our previous report of S1PR2 expression in the cerebellum of SJL mice, 13 which support the target selectivity and specificity of this newly developed S1PR2 radiotracer. 
Discussion
Our previous study revealed that S1PR2 plays an essential role in regulating blood-brain barrier (BBB) function during demyelinating CNS disease. 13 Development of a reliable and noninvasive imaging method that detects S1PR2 expression levels will facilitate better understanding of the neuropathologenesis of MS, especially with regard to the role of S1PR2 in neuroinflammation. Here we reported the design and synthesis of six S1PR2 ligands containing similar core structures as the well-known S1PR2 selective antagonist JTE-013.
The synthesis took 6 -9 steps. The synthesized ligands 5a -5f was tested for binding potency towards S1PR1, S1PR2, and S1PR3 by in vitro competitive cell membrane binding assay. Three compounds showed good binding potency (IC 50 < 10 nM) for S1PR2, and high selectivity over S1PR1 and S1PR3. Based on the in vitro data, we conclude that minor optimization of the functional group may led to significant change on the binding affinities, which will be useful for our future exploring the these structures reported in this manuscript. (decayed to EOB, n > 10), specific activity of 6 -10 Ci/µmol (EOB).
Biodistribution study of [ 11 C]5a indicated a higher cerebellar uptake of the tracer in female SJL mice with
CsA pre-treatment than that in control the group. It is notable that CsA increased the cerebellar uptake of ]5a might also be partly attributed to the relatively low S1PR2 expression level in the brain, since the localization of S1PR2 in SJL mice brain is mainly on endothelial cells. 13 Structural optimization of 5a in the pyrazole-pyridine moiety to avoid P-gp efflux transport and enhance BBB penetration, while retaining binding potency is ongoing. Among the synthesized ligands, compound 5e with a fluoroethoxy group also displayed high binding potency (IC 50 = 8.09 ± 0.91 nM). Here we focused on our first investigation of [ 11 C]5a as a S1PR2 PET ligand. Exploration of 5f and other F-18 labeled ligands is undergoing with our group.
While the pathogenesis of MS involves both genetic susceptibility in terms of immune function and activation, 31 and environmental causes such as Epstein-Barr virus infections, 32 studies focused on sex differences are needed for new insights into hormonal and genetic sex-related factors that may impact on disease susceptibility and to identify new treatment targets. In addition, defined biomarkers that improve diagnostic evaluation and treatment follow-up in a sex-specific fashion are urgently needed. The identification of sex differences in S1PR2 expression and signaling in the neuropathogenesis of CNS autoimmunity 13 is a critical step towards gender-based medicine for the treatment of MS. Targeting S1PR2 may also treat MS without impacting normal immune function. Detection of S1PR2 via a novel, sensitive and noninvasive imaging PET modality will improve the assessment of the receptor in vivo. The current developed tracer meet the above requirement and is able to detect the sexual dimorphism of S1PR2 expression within autoimmune susceptible SJL mice in terms of biodistribution, autoradiography, microPET/CT scans.
Conclusions
We designed and synthesized a spectrum of S1PR2 ligands, chose a ligand that has high binding potency and high selectivity for S1P receptor 1to be labeled with Further exploring the lead structures to identify a promising radioligands for S1PR2 with ability to penetrate the blood brain barrier, may greatly contribute to the diagnosis and treatment of MS and other neuroinflammatory diseases.
Materials and methods
Chemistry
General. All reagents and chemicals were purchased from commercial suppliers and used without further purification unless otherwise stated. Melting points were determined on a MEL-TEMP 3.0 apparatus and are 
6-Bromo-4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine (2) 33
To a solution of 1 (1.0 g, 4.9 mmol) in anisole (10 mL) was added phosphorus oxybromide (2.0 g, 7.0 mmol).
The reaction was heated at 130 °C overnight. Water was added to quench the reaction which was then extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaHCO 3 , and saturated aqueous NaCl. The organic phase was concentrated in vacuo, and the residue was subjected to silica gel chromatography using To a solution of 2 (0.45 g, 1.7 mmol) in ethanol (1.0 mL) was added anhydrous hydrazine (2.8 g, 88 mmol).
The reaction was heated in a sealed tube at 120 °C overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using CH 
2-Chloro-6-methoxyisonicotinoyl azide (4)
To a solution of 2-chloro-6-methoxyisonicotinic acid (0.28 g, 1.5 mmol) in ethyl acetate (3 mL) was added Et 3 N (0.38 g, 3.8 mmol). The solution was cooled to 0 °C and diphenylphosphoryl azide (0.45 g, 1.7 mmol) was added dropwise. The reaction was warmed to room temperature upon addition and was stirred overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using 
N-(2-Chloro-6-methoxypyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-
1-carboxamide (5a)
Under nitrogen, a solution of 4 (40 mg, 0.19 mmol) in toluene (0.5 mL) was refluxed for 3 hours to in situ produce the isocyanate. The reaction mixture was allowed to cool to 50 °C and a solution of 3 (31 mg, 0.14 mmol) in anhydrous THF (1 mL) was added dropwise. The reaction was then stirred at 50 °C overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using CH 
Methyl 2-chloro-6-fluoroisonicotinate (6)
To a solution of methyl 2-chloroisonicotinate (1.0 g, 6.0 mmol) in anhydrous acetonitrile (50 mL) was added silver(II) fluoride (2.6 g, 18 mmol) under nitrogen. The reaction was stirred in a sealed tube at 40 °C overnight.
The suspension was filtered through Celite and the solution was concentrated by rotary evaporation. The residue was subjected to silica gel chromatography using hexane/EtOAc (40/1) as the eluent to afford compound 6 
2-Chloro-6-fluoroisonicotinic acid (7)
To a solution of 6 (0.24 g, 1.3 mmol) in THF (2 mL) was added aqueous lithium hydroxide solution (40 mg in 4 mL water, 1.6 mmol) dropwise at 0 °C . The reaction was stirred at room temperature overnight. 2 M HCl (aq) was added to neutralize the reaction. The mixture was extracted with EtOAc, the combined organic layers were dried over sodium sulfate. The concentrated residue was subjected to silica gel chromatography using 
2-Chloro-6-fluoroisonicotinoyl azide (8)
To a solution of 7 (0.10 g, 0.57 mmol) in anhydrous 1,4-dioxane (2 mL) was added Et 3 N (0.12 g, 1.1 mmol).
The solution was cooled to 0 °C and diphenylphosphoryl azide (0.31 g, 1.1 mmol) was added dropwise. The reaction was warmed to room temperature upon addition and was stirred overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using hexane/EtOAc Chloro-6-fluoropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl) 
2-Chloro-6-(2-methoxyethoxy)isonicotinic acid (9)
To a solution of 2, 6-dichloroisonicotinic acid (1.1 g, 5.7 mmol) in anhydrous THF (5 mL) was added a solution of potassium tert-butoxide (1.6 g, 14.3 mmol) in THF (14 mL) dropwise at 0 °C . 30 min later, 2-methoxyethanol was added dropwise and the reaction was continued at room temperature overnight. 1 N aqueous hydrochloric acid was added to adjust the solution pH to 4. The mixture was extracted with EtOAc, the combined organic layers were dried over sodium sulfate. The concentrated residue was subjected to silica gel chromatography using CH 2 Cl 2 /MeOH (4/1) as the eluent to afford compound 9 as a white solid (1.6 g, 98% yield 
2-Chloro-6-(2-methoxyethoxy)isonicotinoyl azide (10)
To a solution of 9 (0.15 g, 0.65 mmol) in anhydrous 1,4-dioxane (2 mL) was added Et 3 N (0.10 g, 0.97 mmol).
The solution was cooled to 0 °C and diphenylphosphoryl azide (0.27 g, 0.97 mmol) was added dropwise. The reaction was warmed to room temperature upon completion of the addition and was stirred overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using 
N-(2-Chloro-6-(2-methoxyethoxy)pyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-1-carboxamide (5c)
A solution of 10 (126 mg, 0.49 mmol) in toluene (1.2 mL) was refluxed at 120 °C for 3 hours under nitrogen to in situ produce the isocyanate. 
6-Chloro-2-oxo-1, 2-dihydropyridine-4-carboxylic acid (11)
2,6-dichloroisonicotinic acid (2.5 g, 13 mmol) was added to 2 N aqueous NaOH solution (32 mL 
2-chloro-6-(methoxymethoxy)isonicotinate (13)
To a solution of compound 11 (0.87 g, 5 mmol) in CH 2 Cl 2 (100 mL) was added i-Pr 2 NEt (3.2 g, 25 mmol).
The solution was cooled to 0 °C and chloromethyl methyl ether (1.6 g, 20 mmol) was added dropwise. The reaction was warmed to room temperature after completion of the addition and stirred overnight. The solution was quenched with water and extracted with CH 2 Cl 2 . The combined organic phase was washed with saturated aqueous NaHCO 3 , saturated sodium chloride solution, and dried with anhydrous sodium sulfate. The concentrated residue was subjected to silica gel chromatography using CH 2 Cl 2 /MeOH (40/1) as the eluent to afford compound 12 (polar, 876 mg, 67% yield) as a clear liquid and 13 (less polar, 180 mg, 14% yield) as a clear liquid. 
6-Chloro-1-(methoxymethyl)-2-oxo-1,2-dihydropyridine-4-carboxylic acid (14)
To a solution of 12 (1.4 g, 5.3 mmol) in THF (5 mL) was added an aqueous solution of lithium hydroxide (0.17 mg in 10 mL water, 7.0 mmol) dropwise at 0 °C . The reaction was stirred at room temperature for overnight. 2 N HCl solution was added to acidify neutralize the reaction. The mixture was extracted with EtOAc, the combined organic phase was dried over sodium sulfate. The concentrated residue was subjected to silica gel chromatography using CH 
6-Chloro-1-(methoxymethyl)-2-oxo-1,2-dihydropyridine-4-carbonyl azide (15)
To a solution of 14 (0.41 g, 1.9 mmol) in anhydrous 1,4-dioxane (16 mL) was added Et 3 N (0.28 g, 2.8 mmol).
The solution was cooled to 0 °C and diphenylphosphoryl azide (0.77 g, 2.8 mmol) was added dropwise. The reaction was warmed to room temperature upon completion of the addition and stirred overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using hexane/EtOAc 
2-Chloro-6-(methoxymethoxy)isonicotinoyl azide (17)
To a solution of 16 (0.24 g, 1.1 mmol) in anhydrous 1,4-dioxane (5 mL) was added Et 3 N (0.14 g, 1.4 mmol).
The solution was cooled to 0 °C and diphenylphosphoryl azide (0.39 g, 1.4 mmol) was added dropwise. The reaction was warmed to room temperature and stirred overnight. The mixture was concentrated in vacuo, and the residue was subjected to silica gel chromatography using hexane/EtOAc (50/1) as the eluent to afford N-(2-Chloro-6-hydroxypyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl) again and euthanized. The whole brain was quickly harvested, the blood was removed by blotting, and the cerebellum was separated, the remainder of the brain was collected to determine the total brain uptake.
Peripheral organs and tissues, including blood, heart, lung, muscle, fat, thymus, spleen, kidney, and liver, were also collected; all samples were weighed and counted in an automated well counter with a standard dilution of the injectate. Counts were decay-corrected and the %ID/g was calculated. A two-tailed paired Student's t test was used to calculate the standard derivations. A p value less than 0.05 was considered statistically significant.
For the ex vivo autoradiography study, SJL mice were injected with 400-900 µCi of [ 11 C]5a and euthanized 30 min p.i. as described above. The whole brain was quickly removed and snap-frozen. Horizontal sections (100 µm) were cut with a Microm cryotome and mounted on Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA). Frozen slides were directly exposed to film in an imaging cassette for 4 hours at -80 ˚C in the dark. The distribution of radioactivity was visualized by a Fuji Bio-Imaging Analyzer FLA-7000 (Fuji Photo Film Co., Tokyo, Japan). Photo-stimulated luminescence (PSL) from the cerebellum was quantified using Multi Gauge v3.0 software (Fuji Photo Film Co., Tokyo, Japan). Data were background-corrected and expressed as photo-stimulated luminescence signals per square millimeter (PSL/mm 2 ).
Brain microPET imaging was performed using two Siemens microPET scanners (Siemens Preclincial Solutions, Knoxville, TN, USA) -microPET-Focus-F220 and a microPET-Inveon MultiModality scanners.
Imaging studies were done using 19 -25 g SJL mice pretreated with Cyclosporin A. Animals were anesthetized using 2% isoflurane/oxygen and a tail vein catheter placed in the lateral tail vein. Gas anesthesia was maintained at <1.5% isoflurane during the imaging session; each mice was positioned on the scanner bed at least 30 min prior to the tracer injection. Body temperature was maintained using a warming lamp. A dose of 25 mg/kg CsA in saline administered i.v. 30 min prior to radiotracer injection was used for modulation of the BBB efflux transporters. Both CsA and the radiotracer (400-900 µCi of [ 11 C]5a) were administered using an i.v.
catheter placed in the lateral tail vein. The imaging sessions were carried out as 1 h dynamic scan using the MicroPET Focus 220 and Inveon scanners (Siemens Medical Solutions USA). Acquired list mode data were histogrammed into a 3D set of sinograms and binned to the following time frames: 1 × 3 s, 6 × 2 s, 9 × 5 s, 6 × 
